Introduction
Coronary heart disease remains the single largest cause of death [1] , and a major source of disability [2] , in Europe ( Fig. 1 ). Large cohorts with long-term follow-up have been established, such as the British Regional Heart Study [3] , the Whitehall studies of civil servants [4, 5] , the WHO MONICA international study of risk factor and mortality trends [6, 7] , and the Framingham cohort [8] . These and other studies have shown substantial reductions in coronary heart disease mortality from many risk factor changes, as well as medical interventions such as cholesterol lowering [9] , smoking cessation [10] , aspirin [11] , and beta-blockers [12] . If coronary heart disease epidemiology is so well understood, do we need to model it at all? This article will attempt to summarize a variety of models, and illustrate their potential use in overcoming the limitations of traditional epidemiological studies. More specific examples of the use of models to answer questions that could not readily be addressed by traditional research methods will be shown. The current coronary heart disease models, their limitations, and their implications for policy making will then be discussed.
What is a model and how are they used?
In brief, a model is a simplification of reality [13] , ranging from simple, descriptive tools (such as a plan of a house), to systems of mathematical equations, which can explain past disease trends [13, 14] , or predict future events such as disease epidemics [15, 16] . This wide range can cause much ambiguity, confusion, and misunderstanding, unless the model design, assumptions and intended uses are clearly stated and justified. In this review, we cover models which make some attempt to include some of the key variables thought to influence coronary heart disease (these may include levels of the main risk factors, and uptake of treatment combined with demographic information), and some measure of coronary heart disease outcome (usually coronary heart disease mortality). Models designed to evaluate policy options may also include some mechanism for 'intervening' (e.g. introducing a more effective drug treatment or a campaign that reduced population smoking prevalence). To estimate the difference this intervention might make, the model could then be 'run' with and without the intervention.
Recently, 'models' have been extensively used in resource allocation, but these are generally based around 'local' statistics such as population structure and deprivation [17, 18] , rather than disease outcomes, so are not the subject of this review.
Uses in health service planning and decision making
In recent years, there have been calls for a greater use of models in decision-making [13, 19] . For instance, the recent 'Effective Health Care Bulletin' on cholesterol screening and treatment based its recommendations on a costeffectiveness modelling exercise using life table methods [20] . Much work is local in nature, for example, effectiveness of different health promotion interventions have been described by the 'Health Gain' project in London [21] and the Birmingham Health Authority using the PREVENT model [22] . This activity has been aided greatly by the vast improvements in Information Technology. Even ten years ago, relatively simple models required computers of rare power and expense.
By openly and explicitly including local data combined with trial based effectiveness evidence, models can offer increased transparency to the decision making process (provided their assumptions are clearly stated). They can also allow more evidence to be taken into account by combining and integrating different types of data into a coherent whole, such as trials, expert consensus, and routine surveillance. It would be difficult to explicitly take all these sources into account in any other way. However, improved technology potentially allows both practitioners and policy-makers to use these models, without necessarily understanding the modelling assumptions or the limitations of the data.
Uses of models in overcoming the limitations of existing epidemiological studies
Models may be used to overcome some of the limitations of existing epidemiological studies. Some examples are discussed below.
Demographic limitations
Few epidemiological studies have included significant proportions of women, ethnic minorities, elderly subjects, and trends in non-fatal events, risk factors, or treatment uptake. These can be included into the model, even when no direct evidence is available by making explicit assumptions about risk in these groups. This can usefully provide the likely boundaries of an intervention effect in these groups without having to commission new research.
Methodological limitations
Observational studies have contributed enormously to our understanding of coronary heart disease epidemiology. Without these, risk factor modelling would not be feasible. However, observational studies have limitations including time and cost, and potential for bias. Though relatively quick, case-control studies can be notoriously misleading, mainly because exposure is not measured until after disease has occurred [23] . Cohort studies avoid this difficulty, but have certain limitations. They usually enrol people without known disease, therefore such studies may take many decades to complete. Furthermore, the need for repeated assessments throughout the life course has only recently been appreciated [24] . Even randomized trials can be problematic to interpret; not least because narrow inclusion criteria can limit wider generalizations. Models can help assess the importance of these biases, for example by translating trial efficacy into realistic (often reducing) estimates of effectiveness in the general population.
Data limitations
Models can also help explore the potential importance of factors where evidence is sparse or lacking. Although the 'classic' cardiovascular risk factors are well understood, precise roles for 'newer' factors including homocysteine [25] , dietary factors including antioxidant consumption [26] , plasma fibrinogen [27] , and many others are still under debate. The effect of some of these factors may be small, requiring long and expensive studies with large sample sizes to produce reliable estimates. Models can assess the potential effects of these factors by employing a range of 'reasonable' estimates [28] . This sort of 'sensitivity analysis' can systematically examine the influence of uncertainty in the variables (such as compliance with drug therapies among patient groups), or in model assumptions (for example the relationship between a clinical end-point such as cholesterol lowering and coronary heart disease mortality). Even a simple sensitivity analysis could easily assess the 'most likely', 'most optimistic', and 'most pessimistic' plausible values for every variable to provide upper and lower estimates around the 'most likely' result. Such modelling exercises can be a useful preliminary basis for commissioning new primary research.
Making sense of complexity and conflict
Estimates of effectiveness vary substantially for the wealth of interventions and treatments available for coronary heart disease. Current examples include cholesterol lowering therapies and antioxidants. Models can explicitly explore the impact of different estimates of effectiveness or cost-effectiveness. This can help clinicians and policy makers determine promising areas for 
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future research effort, including which subgroups should be prioritized. For instance, models can compare the potential benefits from increasing the uptake of preventive therapies following acute myocardial infarction [29] , or from smoking cessation [30] .
Using models for complex questions not easily addressed by 'traditional' research methods
Explaining mortality declines from coronary heart disease Age-adjusted coronary heart disease mortality rates have fallen since the 1970s by 30-60% in the majority of industrialized countries (Fig. 2 ). Since few epidemiological studies have managed to include the majority of risk factors, treatments, and age groups, models have a key role in attempting to explain these declines. Such models can combine data from many sources to attempt to estimate the proportion of mortality declines that can be attributed to various observed risk factor changes or treatments, or both. For example, the decline resulting from reduction in population mean cholesterol levels can be calculated by applying estimates from trials, systematic reviews and cohort studies. A recent review suggested that a 10% reduction in population mean cholesterol (about 0·6 mmol . l 1 ) should result in a 27% reduction in coronary heart disease mortality at age 60 [34] . By extrapolation, a 1% reduction in population mean cholesterol should lead to a 2·7% reduction in coronary heart disease mortality. There are clearly many assumptions involved in this approach:
(1) this relationship is linear.
(2) results from primary research studies such as the US Framingham population can be applied directly to different populations. (3) appropriate allowances need to be made for time lags between risk factor changes and mortality declines [35] . (4) concomitant risk factor reductions are independent. Here is thus another example where sensitivity analysis is essential. Coronary heart disease models suggest that treatments explain less of the mortality decline than risk factor changes. This has been fairly consistent despite many differences in setting, methodology, and estimates of effectiveness. For example, Beaglehole estimated that the proportion of mortality decline attributable to medical interventions (between 1974 and 1981) was 40% in Auckland, New Zealand [36] , compared with 39.5% in the U.S.A. (from 1968 to 1976) [37] and 40% in Scotland (between 1975 and 1994) [38] . Reassuringly, similar results were obtained when this Scottish model was applied to the New Zealand population between 1982 and 1993 [39] (Fig. 3) . This may be compared with 43% for the U.S.A. (1980) (1981) (1982) (1983) (1984) (1985) (1986) (1987) (1988) (1989) (1990) [40] using a more complex simulation model (Table 1) , the Coronary Heart Disease Policy Model, see Appendix 2). In this analysis [37, 39, 41] , 25% of mortality reduction was attributed to risk factor changes in individuals without coronary heart disease (primary prevention), vs 29% in those with coronary heart disease [40] .
Predicting the impact of interventions on future trends in coronary heart disease mortality
Once developed, some models have been validated e.g. by comparing estimated mortality trends against those actually observed in fresh populations [39] or predicting future events [40] . For example, by extending their Scotland model, Capewell et al. estimated that if the generally low uptake of medical interventions was increased to consistently include 80% of all eligible patients, a further 30 000 deaths might be prevented or postponed each year in the U.K. [29] . Secondary prevention regimens and ACE inhibitors for heart failure offered the greatest potential for further mortality reductions (Fig. 4) .
However, simple models rarely consider the development of other diseases such as cancer, and are thus more limited in assessing the longer-term implications of different policy options. They are, however, a relatively quick and easy starting point to generate ideas. More complex models have been used to evaluate certain interventions. For instance, in the United States, the Coronary Heart Disease Policy Model was used to forecast the (relatively modest) potential gains in life expectancy from risk factor modification, (for instance if males aged 35 ceased smoking, on average they would gain only 2·3 years extra life expectancy) [30] . It would clearly be very difficult to assess these potential gains using traditional epidemiological methods because of the very long time scales. [38, 39] .
Scotland
New Zealand Total treatments 40%
Total risk factors 60% Total treatments 46% Total risk factors 54% AMI treatments 10%
Smoking 36% AMI treatments 12% Smoking 30% Angina (revascularization) 2%
Cholesterol 6% Angina (revascularization) 4% Cholesterol 12% Angina (aspirin) 2%
Population BP (15%)* Angina (aspirin) 3% Population BP (11%)* Heart failure 8% Deprivation 3% Heart failure 7% Deprivation -N/A Hypertension treatment 9%
Other factors 9% Hypertension treatment 7% Other factors 4% Secondary prevention 8% Secondary prevention 12%
*Population blood pressure includes the effect of treatment of individuals for hypertension Table 1 Description of a simulation model 'Static' or 'descriptive models of coronary heart disease simply apply known data on risk factor prevalence, and treatment uptake to population size at one point in time They have been mostly used to assess the proportion of coronary heart disease mortality decline that can be attributed to risk factor changes, as opposed to treatment uptake Unlike 'static' models, 'simulation' models replicate an entire population, and follow it through time Observed age-and sex-specific coronary heart disease incidence and mortality rates are applied to this 'synthetic' cohort Simulation models can take a long time to develop, but generally take into account risk factors and treatments, the development of coronary heart disease and other related diseases such as lung cancer and stroke, and demographic trends They are more flexible in terms of modelling the effects of interventions, for example it is easier to include the influence of lag times Two such 'policy option models' currently in use are PREVENT [31, 32] and POHEM [14] (Population Health Model -developed from the Coronary Heart Disease Policy Model [33] ) [see Appendixes 1 and 2] 
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Similarly, the PREVENT model was used to investigate the effect on mortality of increasing physical activity in 15-64-year-olds in England and Wales [21, 42] . Strategy 1, promoting moderate activity among the sedentary, was more effective in postponing deaths than strategy 2, promoting vigorous activity among those already moderately active. Greater reductions were observed if older age groups and males were also targeted; however, only modest reductions were observed, comparable to a 2% decline in smoking prevalence.
Discussion

Areas for future development
Many existing coronary heart disease models concentrate solely on mortality. Additional important outcomes including increased life expectancy, improved quality of life, and effectiveness should now be incorporated where possible [20] . At present, interventions that predominantly influence quality of life (such as coronary artery bypass grafting) could 'miss out' in a resource allocation process. Most models only include limited numbers and levels of risk factors such as cigarette smoking, blood pressure and cholesterol levels. Other risk factors such as deprivation, antioxidant consumption and other dietary changes need to be investigated. Methodological refinements such as the impact of 'lag times' between risk factor changes and morbidity/ mortality [35] , and adjustments for multiple interventions in the same population, are also required. Commencing with relatively simple descriptive models, results could then be tested against more complex simulation models such as the Coronary Heart Disease Policy Model and POHEM, which can incorporate additional risk factors and treatments, and consider non-coronary heart disease mortality. Assumptions always have to be made, but these are transparent, and can thus be discussed and easily modified.
Implications for health service planners and practitioners
In conclusion, models offer the potential to further our understanding of coronary heart disease epidemiology and facilitate policy formulation. They can help to 'fill in' gaps in our knowledge, make sense of apparently conflicting study results, and combine data from many sources into a coherent whole. Models are particularly useful where there is limited evidence available, or where studies are numerous, but conflicting. Compared with commissioning new primary research, modelling is then a rapid and inexpensive way of assessing the potential impact of uncertainty and disagreement. In future, simple, validated, user-friendly models should provide a useful policy tool. They could quantify the cost-effectiveness of coronary heart disease interventions, and thus help clinicians and policy-makers optimize the use of scarce resources. Health service planners and practitioners therefore need to be able to critically appraise the model used [28] . 
